These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 1768461

  • 1. Alteration of HIV-1 infectivity and neutralization by a single amino acid replacement in the V3 loop domain.
    Ivanoff LA, Looney DJ, McDanal C, Morris JF, Wong-Staal F, Langlois AJ, Petteway SR, Matthews TJ.
    AIDS Res Hum Retroviruses; 1991 Jul; 7(7):595-603. PubMed ID: 1768461
    [Abstract] [Full Text] [Related]

  • 2. The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.
    Zolla-Pazner S, Zhong P, Revesz K, Volsky B, Williams C, Nyambi P, Gorny MK.
    AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1254-8. PubMed ID: 15588347
    [Abstract] [Full Text] [Related]

  • 3. Neutralizing antibodies directed against the V3 loop select for different escape variants in a virus with mutated reverse transcriptase (M184V) than in wild-type human immunodeficiency virus type 1.
    Inouye P, Cherry E, Hsu M, Zolla-Pazner S, Wainberg MA.
    AIDS Res Hum Retroviruses; 1998 Jun 10; 14(9):735-40. PubMed ID: 9643373
    [Abstract] [Full Text] [Related]

  • 4. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
    Losman B, Bolmstedt A, Schønning K, Björndal A, Westin C, Fenyö EM, Olofsson S.
    AIDS Res Hum Retroviruses; 2001 Jul 20; 17(11):1067-76. PubMed ID: 11485624
    [Abstract] [Full Text] [Related]

  • 5. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
    Shibata J, Yoshimura K, Honda A, Koito A, Murakami T, Matsushita S.
    J Virol; 2007 Apr 20; 81(8):3757-68. PubMed ID: 17251298
    [Abstract] [Full Text] [Related]

  • 6. V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1.
    Krachmarov CP, Kayman SC, Honnen WJ, Trochev O, Pinter A.
    AIDS Res Hum Retroviruses; 2001 Dec 10; 17(18):1737-48. PubMed ID: 11788025
    [Abstract] [Full Text] [Related]

  • 7. Studies on the role of the V3 loop in human immunodeficiency virus type 1 envelope glycoprotein function.
    Chiou SH, Freed EO, Panganiban AT, Kenealy WR.
    AIDS Res Hum Retroviruses; 1992 Sep 10; 8(9):1611-8. PubMed ID: 1457207
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity.
    Ivanoff LA, Dubay JW, Morris JF, Roberts SJ, Gutshall L, Sternberg EJ, Hunter E, Matthews TJ, Petteway SR.
    Virology; 1992 Apr 10; 187(2):423-32. PubMed ID: 1546447
    [Abstract] [Full Text] [Related]

  • 10. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY, Luo L, Wainberg MA, Li Y.
    Biol Chem; 1999 Mar 10; 380(3):353-64. PubMed ID: 10223338
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Amino acid substitutions in the V3 loop are responsible for adaptation to growth in transformed T-cell lines of a primary human immunodeficiency virus type 1.
    Harrowe G, Cheng-Mayer C.
    Virology; 1995 Jul 10; 210(2):490-4. PubMed ID: 7618285
    [Abstract] [Full Text] [Related]

  • 15. Conserved V3 loop sequences and transmission of human immunodeficiency virus type 1.
    Shpaer EG, Delwart EL, Kuiken CL, Goudsmit J, Bachmann MH, Mullins JI.
    AIDS Res Hum Retroviruses; 1994 Dec 10; 10(12):1679-84. PubMed ID: 7888227
    [Abstract] [Full Text] [Related]

  • 16. Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1.
    Schønning K, Jansson B, Olofsson S, Hansen JE.
    J Gen Virol; 1996 Apr 10; 77 ( Pt 4)():753-8. PubMed ID: 8627264
    [Abstract] [Full Text] [Related]

  • 17. Independent divergences in the CD4 binding site and V3 loop encoded in two seroprevalent Ugandan HIV-1 clinical isolates.
    Pestano G, Prince A, Guyden J, Ntambi JM, Atkin A, Boto WM.
    J Acquir Immune Defic Syndr (1988); 1993 Aug 10; 6(8):872-80. PubMed ID: 7686222
    [Abstract] [Full Text] [Related]

  • 18. Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity.
    de Jong JJ, Goudsmit J, Keulen W, Klaver B, Krone W, Tersmette M, de Ronde A.
    J Virol; 1992 Feb 10; 66(2):757-65. PubMed ID: 1731110
    [Abstract] [Full Text] [Related]

  • 19. Characterization of a mouse/human chimeric monoclonal antibody (C beta 1) to a principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.
    Matsushita S, Maeda H, Kimachi K, Eda Y, Maeda Y, Murakami T, Tokiyoshi S, Takatsuki K.
    AIDS Res Hum Retroviruses; 1992 Jun 10; 8(6):1107-15. PubMed ID: 1380258
    [Abstract] [Full Text] [Related]

  • 20. The N-terminal of the V3 loop in HIV type 1 gp120 is responsible for its conformation-dependent interaction with cell surface molecules.
    Ling H, Usami O, Xiao P, Gu HX, Hattori T.
    AIDS Res Hum Retroviruses; 2004 Feb 10; 20(2):213-8. PubMed ID: 15018709
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.